Cynthia Lynne Collins's most recent trade in MaxCyte Inc was a trade of 50,790 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| MaxCyte Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 50,790 | 50,790 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 29,210 | 80,889 | - | 0 | Common Stock | |
| Codexis Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 40,983 | 112,157 (0%) | 0% | 0 | Common Stock | |
| Certara Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 15,757 | 15,757 | - | - | Restricted Stock Units | |
| Certara Inc | Cynthia Lynne Collins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 11,928 | 36,089 | - | 0 | Common Stock | |
| Certara Inc | Cynthia Lynne Collins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 11,928 | 0 | - | - | Restricted Stock Units | |
| Codexis Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2025 | 71,174 | 71,174 (0%) | 0% | 0 | Common Stock | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 87,440 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | 08 Jan 2025 | 58,950 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 28,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | Cynthia Lynne Collins | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| MaxCyte Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2024 | 97,698 | 97,698 | - | - | Stock Option (right to buy) | |
| MaxCyte Inc | Cynthia Lynne Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2024 | 51,679 | 51,679 | - | 0 | Common Stock |